Insulin resistance doubles risk of major depressive disorder, study finds

Stanford Medicine scientists have linked insulin resistance to an increased risk of developing major depressive disorder. “If you’re insulin-resistant, your risk of developing major depressive disorder is double that of someone who’s not insulin-resistant, even if you’ve never experienced depression before,” said Natalie Rasgon, MD, Ph.D., professor of psychiatry and behavioral sciences. Upward of 1 in 5 Americans experiences major […]

Read more

FDA Approves Semglee (insulin glargine-yfgn) as First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes

SILVER SPRING, Md., July 28, 2021 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product […]

Read more

Kruppel-like factor 15 controls skeletal muscle fat uptake and utilization

Metabolic diseases, such as obesity and type 2 diabetes, have risen to epidemic proportions in the U.S. and occur in about 30 percent of the population. Skeletal muscle plays a prominent role in controlling the body's glucose levels, which is important for the development of metabolic diseases like diabetes. In a recent study, published in The Journal of Clinical Investigation, […]

Read more

Study explains why antipsychotic medications lead to weight gain, promote metabolic syndrome

Why do patients who receive antipsychotic medications to manage schizophrenia and bipolar disorder quickly gain weight and develop prediabetes and hyperinsulemia? The question remained a mystery for decades, but in a paper published today in Translational Psychiatry, researchers from the University of Pittsburgh School of Medicine finally cracked the enigma. Antipsychotic drugs, scientists showed, not only block dopamine signaling in […]

Read more

Steglatro

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. STEGLATRO® This medicine is subject to additional monitoring. This will allow quick identificationof new safety information. You can help by reporting any side effects you may get.You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems. Ertugliflozin pyroglutamic acid Consumer Medicine Information What is in […]

Read more

Trajenta

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. TRAJENTA CMI0133-09 Tablets linagliptin Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Trajenta. It does not contain all the available information. It does not take the place of talking to your doctor, pharmacist or diabetes educator. All medicines have risks […]

Read more

GenRx Cyproterone 100mg

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. GENRX CYPROTERONE 100 MG TABLETS Contains the active ingredient cyproterone (as cyproterone acetate) Consumer Medicine Information   What is in this leaflet Read this leaflet carefully before taking your medicine. This leaflet answers some common questions about cyproterone. It does not contain all the available information. It […]

Read more

Humalog U200

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. HUMALOG® U200 KwikPen Insulin Lispro (rbe) Consumer Medicine Information What is in this leaflet This leaflet is designed to provide you with answers to some common questions about this medicine. It does not contain all the available information and does not take the place of talking with […]

Read more
1 2 3